Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Inflammation Research
Published in: Inflammation Research 9/2010

01-09-2010 | Review

Anti-inflammatory actions of serine protease inhibitors containing the Kunitz domain

Authors: Hiroshi Shigetomi, Akira Onogi, Hirotaka Kajiwara, Shozo Yoshida, Naoto Furukawa, Shoji Haruta, Yasuhito Tanase, Seiji Kanayama, Taketoshi Noguchi, Yoshihiko Yamada, Hidekazu Oi, Hiroshi Kobayashi

Published in: Inflammation Research | Issue 9/2010

Login to get access

Abstract

Introduction

Protease inhibitors, including the Kunitz, Kazal, serpin and mucus families, play important roles in inhibiting protease activities during homeostasis, inflammation, tissue injury, and cancer progression. Interestingly, in addition to their anti-protease activity, protease inhibitors also often possess other intrinsic properties that contribute to termination of the inflammatory process, including modulation of cytokine expression, signal transduction and tissue remodeling. In this review we have tried to summarize recent findings on the Kunitz family of serine proteinase inhibitors and their implications in health and disease.

Materials and Methods

A systematic search was performed in the electronic databases PubMed and ScienceDirect up to October 2009. We tried to limit the review to anti-inflammatory actions and actions not related to protease inhibition.

Results and Conclusion

Recent studies have demonstrated that the Kunitz inhibitors are not only protease inhibitors, but can also prevent inflammation and tissue injury and subsequently promote tissue remodeling.
Literature
1.
Roberts RM, Mathialagan N, Duffy JY, Smith GW. Regulation and regulatory role of proteinase inhibitors. Crit Rev Eukaryot Gene Expr. 1995;5:385–436.PubMed
2.
Ferencík M, Stvrtinová V, Hulín I, Novák M. Inflammation–a lifelong companion: attempt at a non-analytical holistic view. Folia Microbiol (Praha). 2007;52:159–73.CrossRef
3.
Kobayashi H, Suzuki M, Hirashima Y, Terao T. The protease inhibitor bikunin, a novel anti-metastatic agent. Biol Chem. 2003;384:749–54.CrossRefPubMed
4.
Vincent JP, Lazdunski M. Trypsin-pancreatic trypsin inhibitor association: dynamics of the interaction and role of disulfide bridges. Biochemistry. 1972;11:2967–77.CrossRefPubMed
5.
Astrup T, Nissen U. Urinary trypsin inhibitor (Mingin): transformation into a new trypsin inhibitor by acid hydrolysis or by sialidase. Nature. 1964;203:255–7.CrossRefPubMed
6.
Shimomura T, Denda K, Kitamura A, Kawaguchi T, Kito M, Kondo J, Kagaya S, Qin L, Takata H, Miyazawa K, Kitamura N. Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor. J Biol Chem. 1997;272:6370–6.CrossRefPubMed
7.
Salem HT, Obiekwe BC, Al-Ani AT, Seppälä M, Chard T. Molecular heterogeneity of placental protein 5 (PP5) in late pregnancy serum and plasma: evidence for a heparin-PP5 polymer. Clin Chim Acta. 1980;107:211–5.CrossRefPubMed
8.
Ascenzi P, Bocedi A, Bolognesi M, Spallarossa A, Coletta M, De Cristofaro R, Menegatti E. The bovine basic pancreatic trypsin inhibitor (Kunitz inhibitor): a milestone protein. Curr Protein Pept Sci. 2003;4:231–51.CrossRefPubMed
9.
Day JR, Landis RC, Taylor KM. Aprotinin and the protease-activated receptor 1 thrombin receptor: antithrombosis, inflammation, and stroke reduction. Semin Cardiothorac Vasc Anesth. 2006;10:132–42.CrossRefPubMed
10.
Rattenholl A, Steinhoff M. Proteinase-activated receptor-2 in the skin: receptor expression, activation and function during health and disease. Drug News Perspect. 2008;21:369–81.CrossRefPubMed
11.
Mercer PF, Deng X, Chambers RC. Signaling pathways involved in proteinase-activated receptor1-induced proinflammatory and profibrotic mediator release following lung injury. Ann N Y Acad Sci. 2007;1096:86–8.CrossRefPubMed
12.
Kristeller JL, Roslund BP, Stahl RF. Benefits and risks of aprotinin use during cardiac surgery. Pharmacotherapy. 2008;28:112–24.CrossRefPubMed
13.
Dietrich W. Efficacy and safety of aprotinin in cardiac surgery. Orthopedics. 2004;27:s659–62.
14.
15.
Planès C, Caughey GH. Regulation of the epithelial Na+ channel by peptidases. Curr Top Dev Biol. 2007;78:23–46.CrossRefPubMed
16.
He H, Li W, Tseng DY, Zhang S, Chen SY, Day AJ, Tseng SC. Biochemical characterization and function of complexes formed by hyaluronan and the heavy chains of inter-alpha-inhibitor (HC*HA) purified from extracts of human amniotic membrane. J Biol Chem. 2009;284:20136–46.CrossRefPubMed
17.
Yoneda M, Suzuki S, Kimata K. Hyaluronic acid associated with the surfaces of cultured fibroblasts is linked to a serum-derived 85-kDa protein. J Biol Chem. 1990;265:5247–57.PubMed
18.
Salier JP, Rouet P, Raguenez G, Daveau M. The inter-alpha-inhibitor family: from structure to regulation. Biochem J. 1996;315:1–9.PubMed
19.
Chen L, Mao SJ, McLean LR, Powers RW, Larsen WJ. Proteins of the inter-alpha-trypsin inhibitor family stabilize the cumulus extracellular matrix through their direct binding with hyaluronic acid. J Biol Chem. 1994;269:28282–7.PubMed
20.
Menezes GB, McAvoy EF, Kubes P. Hyaluronan, platelets, and monocytes: a novel pro-inflammatory triad. Am J Pathol. 2009;174:1993–5.CrossRefPubMed
21.
Jiang D, Liang J, Noble PW. Hyaluronan in tissue injury and repair. Annu Rev Cell Dev Biol. 2007;23:435–61.CrossRefPubMed
22.
Zhuo L, Hascall VC, Kimata K. Inter-alpha-trypsin inhibitor, a covalent protein-glycosaminoglycan-protein complex. J Biol Chem. 2004;279:38079–82.CrossRefPubMed
23.
Forteza R, Casalino-Matsuda SM, Monzon ME, Fries E, Rugg MS, Milner CM, Day AJ. TSG-6 potentiates the antitissue kallikrein activity of inter-alpha-inhibitor through bikunin release. Am J Respir Cell Mol Biol. 2007;36:20–31.CrossRefPubMed
24.
Milner CM, Higman VA, Day AJ. TSG-6: a pluripotent inflammatory mediator? Biochem Soc Trans. 2006;34:446–50.CrossRefPubMed
25.
Rugg MS, Willis AC, Mukhopadhyay D, Hascall VC, Fries E, Fülöp C, Milner CM, Day AJ. Characterization of complexes formed between TSG-6 and inter-alpha-inhibitor that act as intermediates in the covalent transfer of heavy chains onto hyaluronan. J Biol Chem. 2005;280:25674–86.CrossRefPubMed
26.
Garantziotis S, Hollingsworth JW, Ghanayem RB, Timberlake S, Zhuo L, Getting SJ, Mahoney DJ, Cao T, Rugg MS, Fries E, Milner CM, Perretti M, Day AJ. The link module from human TSG-6 inhibits neutrophil migration in a hyaluronan- and inter-alpha -inhibitor-independent manner. J Biol Chem. 2002;277:51068–76.CrossRef
27.
Kehlen A, Pachnio A, Thiele K, Langner J. Gene expression induced by interleukin-17 in fibroblast-like synoviocytes of patients with rheumatoid arthritis: upregulation of hyaluronan-binding protein TSG-6. Arthritis Res Ther. 2003;5:R186–92.CrossRefPubMed
28.
Agrawal A, Singh PP, Bottazzi B, Garlanda C, Mantovani A. Pattern recognition by pentraxins. Adv Exp Med Biol. 2009;653:98–116.CrossRefPubMed
29.
Lee GW, Lee TH, Vilcek J. TSG-14, a tumor necrosis factor- and IL-1-inducible protein, is a novel member of the pentaxin family of acute phase proteins. J Immunol. 1993;150:1804–12.PubMed
30.
Scarchilli L, Camaioni A, Bottazzi B, Negri V, Doni A, Deban L, Bastone A, Salvatori G, Mantovani A, Siracusa G, Salustri A. PTX3 interacts with inter-alpha-trypsin inhibitor: implications for hyaluronan organization and cumulus oophorus expansion. J Biol Chem. 2007;282:30161–70.CrossRefPubMed
31.
Souza DG, Amaral FA, Fagundes CT, Coelho FM, Arantes RM, Sousa LP, Matzuk MM, Garlanda C, Mantovani A, Dias AA, Teixeira MM. The long pentraxin PTX3 is crucial for tissue inflammation after intestinal ischemia and reperfusion in mice. Am J Pathol. 2009;174:1309–18.CrossRefPubMed
32.
Adair JE, Stober V, Sobhany M, Zhuo L, Roberts JD, Negishi M, Kimata K, Garantziotis S. Inter-alpha-trypsin inhibitor promotes bronchial epithelial repair after injury through vitronectin binding. J Biol Chem. 2009;284:16922–30.CrossRefPubMed
33.
Jessen TE, Odum L, Johnsen AH. In vivo binding of human inter-alpha-trypsin inhibitor free heavy chains to hyaluronic acid. Biol Chem Hoppe-Seyler. 1994;375:521–6.PubMed
34.
Selbi W, Day AJ, Rugg MS, Fülöp C, de la Motte CA, Bowen T, Hascall VC, Phillips AO. Overexpression of hyaluronan synthase 2 alters hyaluronan distribution and function in proximal tubular epithelial cells. J Am Soc Nephrol. 2006;17:1553–67.CrossRefPubMed
35.
Hinshelwood J, Spencer DI, Edwards YJ, Perkins SJ. Identification of the C3b binding site in a recombinant vWF-A domain of complement factor B by surface-enhanced laser desorption-ionization affinity mass spectrometry and homology modelling: implications for the activity of factor B. J Mol Biol. 1999;294:587–99.CrossRefPubMed
36.
37.
Hamm A, Veeck J, Bektas N, Wild PJ, Hartmann A, Heindrichs U, Kristiansen G, Werbowetski-Ogilvie T, Del Maestro R, Knuechel R, Dahl E. Frequent expression loss of Inter-alpha-trypsin inhibitor heavy chain (ITIH) genes in multiple human solid tumors: a systematic expression analysi. BMC Cancer. 2008;8:25.CrossRefPubMed
38.
Wu R, Cui X, Lim YP, Bendelja K, Zhou M, Simms HH, Wang P. Delayed administration of human inter-alpha inhibitor proteins reduces mortality in sepsis. Crit Care Med. 2004;32:1747–52.CrossRefPubMed
39.
Yang S, Lim YP, Zhou M, Salvemini P, Schwinn H, Josic D, Koo DJ, Chaudry IH, Wang P. Administration of human inter-alpha-inhibitors maintains hemodynamic stability and improves survival during sepsis. Crit Care Med. 2002;30:617–22.CrossRefPubMed
40.
Wachter E, Hochstrasser K. Kunitz-type proteinase inhibitors derived by limited proteolysis of the inter-alpha-trypsin inhibitor, IV. The amino acid sequence of the human urinary trypsin inhibitor isolated by affinity chromatography. Hoppe Seylers Z Physiol Chem. 1981;362:1351–5.PubMed
41.
Fries E, Blom AM. Bikunin-not just a plasma proteinase inhibitor. Int J Biochem Cell Biol. 2000;32:125–37.CrossRefPubMed
42.
Yoshida E, Sumi H, Tsushima H, Maruyama M, Mihara H. Distribution and localization of inter-alpha-trypsin inhibitor and its active component acid-stable proteinase inhibitor: comparative immunohistochemical study. Inflammation. 1991;15:71–9.CrossRefPubMed
43.
Yoshihara Y, Plaas A, Osborn B, Margulis A, Nelson F, Stewart M, Rugg MS, Milner CM, Day AJ, Nemoto K, Sandy JD. Superficial zone chondrocytes in normal and osteoarthritic human articular cartilages synthesize novel truncated forms of inter-alpha-trypsin inhibitor heavy chains which are attached to a chondroitin sulfate proteoglycan other than bikunin. Osteoarthritis Cartilage. 2008;16:1343–55.CrossRefPubMed
44.
Itoh H, Tomita M, Kobayashi T, Uchino H, Maruyama H, Nawa Y. Expression of inter-alpha-trypsin inhibitor light chain (bikunin) in human pancreas. J Biochem. 1996;120:271–5.PubMed
45.
Lin SD, Takikawa Y, Endo R, Suzuki K. Proinflammatory cytokines up-regulate synthesis and secretion of urinary trypsin inhibitor in human hepatoma HepG2 cells. Hepatol Res. 2004;29:243–8.CrossRefPubMed
46.
Imada K, Ito A, Kanayama N, Terao T, Mori Y. Urinary trypsin inhibitor suppresses the production of interstitial procollagenase/proMMP-1 and prostromelysin 1/proMMP-3 in human uterine cervical fibroblasts and chorionic cells. FEBS Lett. 1997;417:337–40.CrossRefPubMed
47.
Zaitsu M, Hamasaki Y, Tashiro K, Matsuo M, Ichimaru T, Fujita I, Tasaki H, Miyazaki S. Ulinastatin, an elastase inhibitor, inhibits the increased mRNA expression of prostaglandin H2 synthase-type 2 in Kawasaki disease. J Infect Dis. 2000;181:1101–9.CrossRefPubMed
48.
Kobayashi H, Suzuki M, Sun GW, Hirashima Y, Terao T. Suppression of urokinase-type plasminogen activator expression from human ovarian cancer cells by urinary trypsin inhibitor. Biochim Biophys Acta. 2000;1481:310–6.PubMed
49.
Yamaguchi Y, Ohshiro H, Nagao Y, Odawara K, Okabe K, Hidaka H, Ishihara K, Uchino S, Furuhashi T, Yamada S, Mori K, Ogawa M. Urinary trypsin inhibitor reduces C-X-C chemokine production in rat liver ischemia/reperfusion. J Surg Res. 2000;94:107–15.CrossRefPubMed
50.
Aosasa S, Ono S, Mochizuki H, Tsujimoto H, Ueno C, Matsumoto A. Mechanism of the inhibitory effect of protease inhibitor on tumor necrosis factor alpha production of monocytes. Shock. 2001;15:101–5.CrossRefPubMed
51.
Molor-Erdene P, Okajima K, Isobe H, Uchiba M, Harada N, Okabe H. Urinary trypsin inhibitor reduces LPS-induced hypotension by suppressing tumor necrosis factor-alpha production through inhibition of Egr-1 expression. Am J Physiol Heart Circ Physiol. 2005;288:H1265–71.CrossRefPubMed
52.
Molor-Erdene P, Okajima K, Isobe H, Uchiba M, Harada N, Shimozawa N, Okabe H. Inhibition of lipopolysaccharide-induced tissue factor expression in monocytes by urinary trypsin inhibitor in vitro and in vivo. Thromb Haemost. 2005;94:136–45.PubMed
53.
Wu YJ, Ling Q, Zhou XH, Wang Y, Xie HY, Yu JR, Zheng SS. Urinary trypsin inhibitor attenuates hepatic ischemia-reperfusion injury by reducing nuclear factor-kappa B activation. Hepatobiliary Pancreat Dis Int. 2009;8:53–8.PubMed
54.
Wakahara K, Kobayashi H, Yagyu T, Matsuzaki H, Kondo T, Kurita N, Sekino H, Inagaki K, Suzuki M, Kanayama N, Terao T. Bikunin suppresses lipopolysaccharide-induced lethality through down-regulation of tumor necrosis factor- alpha and interleukin-1 beta in macrophages. J Infect Dis. 2005;191:930–8.CrossRefPubMed
55.
Suzuki M, Kobayashi H, Tanaka Y, Hirashima Y, Kanayama N, Takei Y, Saga Y, Suzuki M, Itoh H, Terao T. Bikunin target genes in ovarian cancer cells identified by microarray analysis. J Biol Chem. 2003;278:14640–6.CrossRefPubMed
56.
Kanayama N, Maehara K, She L, Belayet HM, Khatun S, Tokunaga N, Terao T. Urinary trypsin inhibitor suppresses vascular smooth muscle contraction by inhibition of Ca2 + influx. Biochim Biophys Acta. 1998;1381:139–46.PubMed
57.
Kanayama S, Yamada Y, Onogi A, Shigetomi H, Ueda S, Tsuji Y, Haruta S, Kawaguchi R, Yoshida S, Sakata M, Sado T, Kitanaka T, Oi H, Yagyu T, Kobayashi H. Bikunin suppresses expression of pro-inflammatory cytokines induced by lipopolysaccharide in neutrophils. J Endotoxin Res. 2007;13:369–76.CrossRefPubMed
58.
Yu JR, Yan S, Liu XS, Wu YJ, Fu PF, Wu LH, Zheng SS. Attenuation of graft ischemia-reperfusion injury by urinary trypsin inhibitor in mouse intestinal transplantation. World J Gastroenterol. 2005;11:1605–9.PubMed
59.
Inoue K, Takano H, Yanagisawa R, Sakurai M, Shimada A, Yoshino S, Sato H, Yoshikawa T. Protective role of urinary trypsin inhibitor in acute lung injury induced by lipopolysaccharide. Exp Biol Med. (Maywood). 2005;230:281–7.
60.
Zhou LW, Wang YL, Yan XT, He XH. Urinary trypsin inhibitor treatment ameliorates acute lung and liver injury resulting from sepsis in a rat model. Saudi Med J. 2008;29:368–73.PubMed
61.
El Maradny E, Kanayama N, Halim A, Maehara K, Kobayashi T, Terao T. Effects of urinary trypsin inhibitor on myometrial contraction in term and preterm deliveries. Gynecol Obstet Invest. 1996;41:96–102.CrossRefPubMed
62.
Pugia MJ, Valdes R Jr, Jortani SA. Bikunin (urinary trypsin inhibitor): structure, biological relevance, and measurement. Adv Clin Chem. 2007;44:223–45.CrossRefPubMed
63.
Rakic JM, Maillard C, Jost M, Bajou K, Masson V, Devy L, Lambert V, Foidart JM, Noel A. Role of plasminogen activator-plasmin system in tumor angiogenesis. Cell Mol Life Sci. 2003;60:463–73.CrossRefPubMed
64.
Yagyu T, Kobayashi H, Matsuzaki H, Wakahara K, Kondo T, Kurita N, Sekino H, Inagaki K. Enhanced spontaneous metastasis in bikunin-deficient mice. Int J Cancer. 2006;118:2322–8.CrossRefPubMed
65.
Tsui KH, Chang PL, Feng TH, Chung LC, Hsu SY, Juang HH. Down-regulation of matriptase by overexpression of bikunin attenuates cell invasion in prostate carcinoma cells. Anticancer Res. 2008;28:1977–83.PubMed
66.
Liu J, Guo Q, Chen B, Yu Y, Lu H, Li YY. Cathepsin B and its interacting proteins, bikunin and TSRC1, correlate with TNF-induced apoptosis of ovarian cancer cells OV-90. FEBS Lett. 2006;580:245–50.CrossRefPubMed
67.
Parr C, Jiang WG. Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells. Int J Cancer. 2006;119:1176–83.CrossRefPubMed
68.
Kirchhofer D, Peek M, Li W, Stamos J, Eigenbrot C, Kadkhodayan S, Elliott JM, Corpuz RT, Lazarus RA, Moran P. Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1. J Biol Chem. 2003;278:36341–9.CrossRefPubMed
69.
Denda K, Shimomura T, Kawaguchi T, Miyazawa K, Kitamura N. Functional characterization of Kunitz domains in hepatocyte growth factor activator inhibitor type 1. J Biol Chem. 2002;277:14053–9.CrossRefPubMed
70.
Itoh H, Kataoka H, Meng JY, Hamasuna R, Kitamura N, Koono M. Mouse hepatocyte growth factor activator inhibitor type 1 (HAI-1) and type 2 (HAI-2)/placental bikunin genes and their promoters. Biochim Biophys Acta. 2001;1519:92–5.PubMed
71.
Morris MR, Gentle D, Abdulrahman M, Maina EN, Gupta K, Banks RE, Wiesener MS, Kishida T, Yao M, The B, Latif F, Maher ER. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma. Cancer Res. 2005;65:4598–606.CrossRefPubMed
72.
Tanaka H, Fukushima T, Yorita K, Kawaguchi M, Kataoka H. Tissue injury alters the site of expression of hepatocyte growth factor activator inhibitor type 1 in bronchial epithelial cells. Hum Cell. 2009;22:11–7.PubMedCrossRef
73.
Szabo R, Molinolo A, List K, Bugge TH. Matriptase inhibition by hepatocyte growth factor activator inhibitor-1 is essential for placental development. Oncogene. 2007;26:1546–56.CrossRefPubMed
74.
Torres-Collado AX, Kisiel W, Iruela-Arispe ML, Rodríguez-Manzaneque JC. ADAMTS1 interacts with, cleaves, and modifies the extracellular location of the matrix inhibitor tissue factor pathway inhibitor-2. J Biol Chem. 2006;281:17827–37.CrossRefPubMed
75.
Chand HS, Foster DC, Kisiel W. Structure, function and biology of tissue factor pathway inhibitor-2. Thromb Haemost. 2005;94:1122–30.PubMed
76.
Schmidt AE, Chand HS, Cascio D, Kisiel W, Bajaj SP. Crystal structure of Kunitz domain 1 (KD1) of tissue factor pathway inhibitor-2 in complex with trypsin. Implications for KD1 specificity of inhibition. J Biol Chem. 2005;280:27832–8.CrossRefPubMed
77.
Crawley JT, Lane DA. The haemostatic role of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol. 2008;28:233–42.CrossRefPubMed
78.
Kato H. Regulation of functions of vascular wall cells by tissue factor pathway inhibitor: basic and clinical aspects. Arterioscler Thromb Vasc Biol. 2002;22:539–48.CrossRefPubMed
79.
Lanir N, Aharon A, Brenner B. Procoagulant and anticoagulant mechanisms in human placenta. Semin Thromb Hemost. 2003;29:175–84.CrossRefPubMed
80.
Guo H, Lin Y, Zhang H, Liu J, Zhang N, Li Y, Kong D, Tang Q, Ma D. Tissue factor pathway inhibitor-2 was repressed by CpG hypermethylation through inhibition of KLF6 binding in highly invasive breast cancer cells. BMC Mol Biol. 2007;8:110.CrossRefPubMed
81.
Liu YY, Stack SM, Lakka SS, Khan AJ, Woodley DT, Rao JS, Rao CN. Matrix localization of tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor (TFPI-2/MSPI) involves arginine-mediated ionic interactions with heparin and dermatan sulfate: heparin accelerates the activity of TFPI-2/MSPI toward plasmin. Arch Biochem Biophys. 1999;370:8–112.CrossRef
82.
Lin YF, Zhang N, Guo HS, Kong DS, Jiang T, Liang W, Zhao ZH, Tang QQ, Ma D. Recombinant tissue factor pathway inhibitor induces apoptosis in cultured rat mesangial cells via its Kunitz-3 domain and C-terminal through inhibiting PI3-kinase/Akt pathway. Apoptosis. 2007;12:2163–73.CrossRefPubMed
83.
Ivanciu L, Gerard RD, Tang H, Lupu F, Lupu C. Adenovirus-mediated expression of tissue factor pathway inhibitor-2 inhibits endothelial cell migration and angiogenesis. Arterioscler Thromb Vasc Biol. 2007;27:310–6.CrossRefPubMed
84.
Lwaleed BA, Bass PS. Tissue factor pathway inhibitor: structure, biology and involvement in disease. J Pathol. 2006;208:327–39.CrossRefPubMed
Metadata
Title
Anti-inflammatory actions of serine protease inhibitors containing the Kunitz domain
Authors
Hiroshi Shigetomi
Akira Onogi
Hirotaka Kajiwara
Shozo Yoshida
Naoto Furukawa
Shoji Haruta
Yasuhito Tanase
Seiji Kanayama
Taketoshi Noguchi
Yoshihiko Yamada
Hidekazu Oi
Hiroshi Kobayashi
Publication date
01-09-2010
Publisher
SP Birkhäuser Verlag Basel
Published in
Inflammation Research / Issue 9/2010
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-010-0205-5

Other articles of this Issue 9/2010

Inflammation Research 9/2010 Go to the issue

Original Research Paper

Protective effect of gastrin-releasing peptide receptor antagonist in carrageenan-induced pleural inflammation in rats

Original Research Paper

Inadequate cytoplasmatic calcium signals in alveolar macrophages after cardiac surgery

Original Research Paper

Flavonoid combinations cause synergistic inhibition of proinflammatory mediator secretion from lipopolysaccharide-induced RAW 264.7 cells

Original Research Paper

A novel model of inflammatory pain in human skin involving topical application of sodium lauryl sulfate

Original Research Paper

The selective COX-2 inhibitor Etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment

Original Research Paper

Contribution of bone marrow-derived cells to the pro-inflammatory effects of protease-activated receptor-2 in colitis

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits